Oxford BioDynamics (LON:OBD) Issues Quarterly Earnings Results

Oxford BioDynamics (LON:OBD) posted its earnings results on Tuesday. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative return on equity of 316.67% and a negative net margin of 1,018.54%.The business had revenue of GBX 69 million for the quarter.

Oxford BioDynamics Stock Down 20.0%

LON:OBD traded down GBX 0.03 during mid-day trading on Tuesday, hitting GBX 0.12. The company had a trading volume of 203,065,281 shares, compared to its average volume of 16,105,363. The business has a fifty day simple moving average of GBX 0.19 and a 200-day simple moving average of GBX 0.23. The firm has a market capitalization of £5.15 million, a price-to-earnings ratio of -0.15 and a beta of 0.42. Oxford BioDynamics has a 1 year low of GBX 0.09 and a 1 year high of GBX 0.78. The company has a current ratio of 0.88, a quick ratio of 2.80 and a debt-to-equity ratio of 457.97.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.